Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine + Sintilimab in Advanced NSQ NSCLC
NCT05849246Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Jul 2023
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tusamitamab ravtansine in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Innovent Biologics. Started Jul 2023; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05849246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849246.